Bioenergy Introduces Corvalen M(R) as a Natural Treatment Option for Fibromyalgia Symptoms

MINNEAPOLIS, May 27 /PRNewswire/ -- Fibromyalgia affects as many as one in 50 Americans, 90 percent of whom are women. Yet, despite its nearly epidemic status, patients still often rely on pharmaceutical options solely for treatment. That's why Bioenergy Life Science, Inc. (www.bioenergy.com) has introduced Corvalen M®, a natural treatment option for fibromyalgia symptoms.  

Fibromyalgia is a syndrome mainly associated with widespread muscular pains and fatigue. The exact causes of fibromyalgia are unknown; however, patients with fibromyalgia have been shown to have an alteration in muscle adenine nucleotide metabolism, leading to depleted energy reserves (1).  As an essential compound in increasing muscular energy pools and reducing metabolic strain in affected muscles, Corvalen M® has been shown to be effective against fibromyalgia symptoms (2).

Corvalen M® comprises D-Ribose, a simple, 5-carbon monosaccharide, or pentose sugar. D-Ribose helps accelerate the formation of adenosine triphosphate (ATP), the primary energy source of all living cells, which can lead to subsequent tissue recovery for fibromyalgia patients.

"Having had Chronic Fatigue Syndrome and Fibromyalgia back in 1975, I know what patients are going through," says Dr. Jacob Teitelbaum, M.D, one of the primary researchers of this study and the medical director of the Fibromyalgia and Fatigue Centers, Inc. "The good news is these illnesses have become very treatable!"

Teitelbaum conducted a multi-center study, in which 53 health practitioners enrolled 257 patients who had been diagnosed with fibromyalgia and/or chronic fatigue syndrome. Each patient was given D-Ribose (Corvalen) at a dose of five grams per day for three weeks. All patients were measured for changes in energy, sleep, cognitive function, pain and overall well-being.

Teitelbaum noted improvement in the first week of treatment. After three weeks, results showed statistically significant improvements in all five parameters, More than half of the study's patients showed improvement in energy (61 percent), followed by a 37 percent increase in overall well-being.  

Bioenergy Life Science, Inc. focuses its core technology on D-Ribose®, the primary ingredient in the Corvalen Medical Food family of products, which include Corvalen®, Corvalen M® and Corvalen® Chewable Wafers. D-Ribose® is the only ribose to receive GRAS (generally regarded as safe) affirmation, no questions letter from the Food and Drug Administration (FDA). D-Ribose® is found also in many energy drinks, bars and supplements.

For more information, contact Renee Cooper of Christie Communications at 805-969-3744 or [email protected].

(1)  Gebhart B, Jorgenson JA. Benefit of ribose in a patient with fibromyalgia. Pharmacotherapy. 2004 Nov;24(11):1646-8

(2)  Teitelbaum J, Johnson C, Cyr J. The Use of D-Ribose in Chronic Fatigue Syndrome and Fibromyalgia: A Pilot Study. The Journal of Alternative and Complementary Medicine. 2006 12(9):857-862

SOURCE Bioenergy Life Science, Inc.